Sage Therapeutics faced the wrath of finicky investors on March 23 as its shares dropped more 20% in early morning trading in response to a scathing report from a hedge fund that has a short positions on the stock. The overblown reaction is a good indicator of market climate.
The biotech's shares dipped precipitously in morning trading, but recovered slightly as the trading day went on. Shares were down...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
